Figure 1.

Response to ibrutinib. Response to ibrutinib is shown at both preplanned response assessments at 32 and 48 weeks. Patients with either a CR or a PR were considered responders. Patients who died before the 32-week response assessment and those who were off-study and therefore not assessed for response are shown. These data are also found in supplemental Table 5. One patient is still receiving treatment but has not reached the 48-week assessment and is included in the 32-week assessment and best response for any cycle totals.